CANCER BUZZ

CANCERBUZZ speaks with guests at the 2024 NOC Gala event about what they are looking for at the conference.

Guests:

Una Hopkins, DNP, MSN, BSN, FNP-BC, NE-BC, FACCC, RN

ACCC President-Elect

Director for Research and Evidence Based Practice

Montefiore Medical Center

Bronx, NY

Nadine Barrett, PhD, MA, MS

ACCC President

Senior Associate Dean, Research Equity and Community Engagement

Wake Forest School of Medicine

Durham, North Carolina

Russell C. Langan, MD, FACS, FSSO

Director of Surgical Oncology

RWJBarnabas Health and the Rutgers Cancer Institute of New Jersey

Jersey City, New Jersey

Brittany McArn, OPN-CG, CPPN

ACCC Advisory Committee

Financial Navigation Manager, Outpatient Oncology Services

FirstHealth of the Carolinas, Inc.

Pinehurst, NC

Beau Palin

Co-Founder & COO

Colla Health

JiaJoyce Conway, DNP, CRNP, AOCNP

ACCC Board of Trustees

Nurse Practitioner

Cancer Care Associates of York

York, PA

Resources:

ACCC 41st National Oncology Conference

CANCERBUZZ speaks with Terry Keys about his NOC session titled Empowering Partnerships: Enhancing Cancer Research Through Patient Advocacy.

Guest:

Terry Keys

Patient Advocacy Manager

Staff Senator – President's Advisory Committee

University of Kentucky Markey Cancer Center

Lexington, KY

Resources:

ACCC 41st National Oncology Conference

CANCERBUZZ speaks with ACCC President Dr. Nadine Barrett about this year's NOC theme: Realizing Innovation. Listen to what's new in conversations and oncology education in 2024.

Guest:

Nadine Barrett, PhD, MA, MS

ACCC President

Senior Associate Dean, Research Equity and Community Engagement

Wake Forest School of Medicine

Durham, North Carolina

Resources:

ACCC 41st National Oncology Conference

CANCERBUZZ speaks with ACCC's Immediate Past President Dr. Olalekan Ajayi about the international panel held at NOC this year, where cancer care providers from around the world share and learn from common challenges and best practices.

Guest:

Olalekan Ajayi, PharmD, MBA

Chief Operating Officer

Highlands Oncology Group

Fayetteville, Arkansas

Resources:

ACCC 41st National Oncology Conference

CANCERBUZZ speaks with Magbis Nunez Love about her NOC session titled Renacer: Culturally Tailored, Patient-Centered Survivorship Care Improves Access and Outcomes.

Guest:

Magbis Nunez Love, MHR

Community Liaison

Atrium Health Levine Cancer/Wake Forest Baptist Comprehensive Cancer Center

Charlotte, NC

Resources:

ACCC 41st National Oncology Conference

Discussions from the ACCC 50th AMCCBS held from February 28 to March 1, 2024, were used to develop the 2024 Trending Now in Cancer Care Part 1 and Part 2 reports. Download Part 1 for a look at trends in collaborative care delivery models, community engagement in cancer prevention, oncology workforce challenges, and the provision of comprehensive cancer care services. Download Part 2 for an examination of 4 key topics: artificial and business intelligence technology; EHR integration in precision medicine; payer, manufacturer, and supply chain challenges; and key partnerships in research and clinical trials.

Guest:

Meagan O' Neill Executive Director Association of Cancer Care Centers

Quote:

"[In terms of AI], ACCC starting is with the here and now. So, what's available today that has been proven to save time or reduce burnout or be an effective tool for better patient care, for better access. Those solutions are what we're focused on this year and into 2025 so that we can help our members cut through the noise in this space."

"[Prior authorization] is a very big issue because it takes so much time, and it creates this additional burden for our cancer care team members. And if you look at the impact on patient care, that's really where the conversation needs to be focused because there is a significant and detrimental impact on patient care."

Participate in sessions and discussions that will inform the 2025 Trending Now in Cance Care Delivery report by attending the ACCC 51st Annual Meeting & Cancer Center Business Summit, March 5-7 in Washington, DC.

Additional Resources:

2024 Trending Now in Cancer Care: Part 1

2024 Trending Now in Cancer Care: Part 2

2023 Trending Now in Cancer Care: Part 1

2023 Trending Now in Cancer Care Part 2

Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population.

"Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities." – Dr. Jeff Sharman, MD

"A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy." – Dr. Jeff Sharman, MD

Jeff Sharman, MD

Medical Director of Hematology Research, US Oncology

Director of Research

Willamette Valley Cancer Institute

Eugene, Oregon

This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society.

Resources

Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC

Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series:

Update on New Therapies: https://vimeo.com/942756449

BTK Inhibitors in MCL: https://vimeo.com/942755401

R/R MCL Case Studies: https://vimeo.com/942754652

BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive

HCP Fact Sheet: Facts About CAR T-cell Therapy

The CAR T-cell Therapy Process

Patient-Caregiver CAR T-cell Therapy Facts

Learn About CAR T-cell Therapy

Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

Designing a health equity playbook starts with a deep understanding of the patients you serve. Successful playbooks have components that build on the patient experience, the protocols that are in place to ensure the cancer program is meeting the unique needs of all its patients, and staff education and and training on how to best serve those different patient populations. When developing a health equity playbook, cancer programs need to break down existing silos and ensure that all key players are involved in developing strategies and identifying how the cancer program is going to use this tool to improve care.

Guest:

Maria Hernandez, PhD President and COO Impact4Health, LLC

Quote:

"Hopefully, we will get to a place in the future where every single health system's strategy for providing the best quality of care always has equity in mind…a hospital system of the future will have in its DNA the ability to look at its operations and understand that health equity must be in everything we do."

Hear more about how to develop and activate a health equity playbook in the 2-hour ACHE accredited session, More than Words: Leveraging Governance and Partnerships to Advance Health Equity, at the ACCC 41st National Oncology Conference, October 9-11, 2024, in Minneapolis, Minnesota.

Additional Resources:

Healthcare With Community in Its DNA: Exploring Montefiore Health System's Community Health Worker Institute Model

Community Engagement: Increasing Access to Supportive

Population Health Navigators: An Innovative Approach for Supporting Underserved Patients

The Role of Population Health Navigators — [MINI PODCAST] Ep 101

Addressing Social Determinants of Health through a Medical-Legal Partnership — [PODCAST] EP 88

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.

"The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. " –Dr. Nirav Shah, MD, MSHP

"We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy." –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC

Nirav Shah, MD, MSHP Associate Professor of Medicine Medical College of Wisconsin Division of Hematology and Oncology

Milwaukee, Wisconsin

Kirollos Hanna, PharmD, BCPS, PCOP, FACCC

Assistant Professor of Pharmacy, Mayo Clinic

Director of Pharmacy

Minnesota Oncology

St. Paul, Minnesota

This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society.

Resources

Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC

Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series:

Update on New Therapies: https://vimeo.com/942756449

BTK Inhibitors in MCL: https://vimeo.com/942755401

R/R MCL Case Studies: https://vimeo.com/942754652

BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive

HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf

The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf

Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf

Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf

Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.

“The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP

“We’re not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it’s going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC

Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology 

Milwaukee, Wisconsin 

Kirollos Hanna, PharmD, BCPS, PCOP, FACCC 

Assistant Professor of Pharmacy, Mayo Clinic 

Director of Pharmacy 

Minnesota Oncology  

St. Paul, Minnesota 

This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society.

Resources

Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC 

Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series:

Update on New Therapies: https://vimeo.com/942756449

BTK Inhibitors in MCL: https://vimeo.com/942755401

R/R MCL Case Studies: https://vimeo.com/942754652

BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology 

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive 

HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf  

The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf  

Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf  

Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf   

Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf